Literature DB >> 18288182

A genetic framework for improving arrhythmia therapy.

Björn C Knollmann1, Dan M Roden.   

Abstract

Abnormalities in heart rhythm continue to cause high rates of illness and death. Better treatment could be provided by solving two main challenges: the early identification of patients who are at risk, and the characterization of molecular pathways that culminate in arrhythmias. By analysing mechanisms that increase susceptibility to arrhythmia in individuals with genetic syndromes, it might be possible to improve current therapies and to develop new ways to treat and prevent common arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288182     DOI: 10.1038/nature06799

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  36 in total

1.  Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification.

Authors:  Jun Wang; Elzbieta Klysik; Subeena Sood; Randy L Johnson; Xander H T Wehrens; James F Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

3.  Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders.

Authors:  Björn C Knollmann
Journal:  Heart Rhythm       Date:  2010-07-29       Impact factor: 6.343

Review 4.  Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Michela Faggioni; Dmytro O Kryshtal; Björn C Knollmann
Journal:  Pediatr Cardiol       Date:  2012-03-16       Impact factor: 1.655

5.  Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram.

Authors:  Arash Sadrieh; Stefan A Mann; Rajesh N Subbiah; Luke Domanski; John A Taylor; Jamie I Vandenberg; Adam P Hill
Journal:  J Physiol       Date:  2013-04-03       Impact factor: 5.182

6.  Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.

Authors:  Ying Ke; Mark J Hunter; Chai Ann Ng; Matthew D Perry; Jamie I Vandenberg
Journal:  J Biol Chem       Date:  2014-04-02       Impact factor: 5.157

Review 7.  Pathophysiology, prevention, and treatment of commotio cordis.

Authors:  Mark S Link
Journal:  Curr Cardiol Rep       Date:  2014       Impact factor: 2.931

8.  Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.

Authors:  Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

9.  Molecular mechanisms of inherited arrhythmias.

Authors:  Cordula M Wolf; Charles I Berul
Journal:  Curr Genomics       Date:  2008-05       Impact factor: 2.236

10.  Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias.

Authors:  William S Bush; Dana C Crawford; Charles Alexander; Alfred L George; Dan M Roden; Marylyn D Ritchie
Journal:  Pharmacogenomics       Date:  2009-06       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.